Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemomab Therapeutics Ltd.CMMB · Entity 7653 | Chief Financial Officer | March 18, 2026 | April 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemomab Therapeutics Ltd.
Report date March 18, 2026 · Filed April 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 9,728 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 9,728 |
| American Depositary SharesSEC Table I · non-derivative | Direct | 15,222 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,222 F1: The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on October 1, 2024 and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028. |
| American Depositary SharesSEC Table I · non-derivative | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,500 F2: The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on April 10, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029. |
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $39.31 · Expires 2031-11-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: The options reported in this row were granted to the Reporting Person by the Issuer on November 11, 2021, and are fully vested and exercisable as of the date of this report. |
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $8.44 · Expires 2032-11-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: The options reported in this row were granted to the Reporting Person by the Issuer on November 8, 2022, and vest and become exercisable according to following schedule: 25% on November 8, 2023, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on November 8, 2026. |
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2033-06-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F5: The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 14, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on October 1, 2024 and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.
F2: The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on April 10, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.
F3: The options reported in this row were granted to the Reporting Person by the Issuer on November 11, 2021, and are fully vested and exercisable as of the date of this report.
F4: The options reported in this row were granted to the Reporting Person by the Issuer on November 8, 2022, and vest and become exercisable according to following schedule: 25% on November 8, 2023, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on November 8, 2026.
F5: The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 14, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 15, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2023 Filed Jun 16, 2023 20:03 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 102,860 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001178913-23-002227 · ownership.xml · derivative · entry 2 Fatal Sigal · CIK 0001850994 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,860 Underlying: American Depositary Shares · 102,860 shares Expires 2033-06-14 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F3 · derivative.exercise_date: Options granted under the Company's 2017 Equity-Based Incentive Plan (the "Plan") on June 14, 2023; 25% of the options vest and become exercisable following 12 months from the grant thereof and an additional 6.25% vests at the end of each calendar quarter thereafter such that the options are fully vested and exercisable on June 14, 2027, subject to acceleration upon a change in control pursuant to the terms of the Option Agreement ("CIC") by and between the Reporting Person and the Issuer and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan). F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| November 08, 2022 Filed Jun 16, 2023 20:03 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 29,400 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001178913-23-002227 · ownership.xml · derivative · entry 3 Fatal Sigal · CIK 0001850994 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: American Depositary Shares · 29,400 shares Expires 2032-11-08 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this form 4 for informational purposes only. F4 · derivative.exercise_date: These options vest and become exercisable pursuant to the following schedule: 25% of the options shall vest on November 8, 2023, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan). F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| November 11, 2021 Filed Jun 16, 2023 20:03 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 35,600 | $0.00 Strike: $9.83 | $0.00 |
DisclosureSEC source: 0001178913-23-002227 · ownership.xml · derivative · entry 4 Fatal Sigal · CIK 0001850994 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,600 Underlying: American Depositary Shares · 35,600 shares Expires 2031-11-11 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this form 4 for informational purposes only. F5 · derivative.exercise_date: These options vest and become exercisable pursuant to the following schedule: 25% of the options vested on November 11, 2022, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control pursuant ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan). F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| May 07, 2021 Filed May 10, 2021 20:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 35,653 | $0.00 Strike: $27.26 | $0.00 |
DisclosureSEC source: 0001104659-21-063814 · tm2115776-1_4seq1.xml · derivative · entry 1 Fatal Sigal · CIK 0001850994 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,653 Underlying: American Depositary Shares · 35,653 shares Expires 2031-05-07 F1 · derivative.exercise_date: These options vest and become exercisable pursuant to the following schedule: 25% of the options shall vest on the first anniversary of November 7, 2020, and the remainder shall vest over three years in quarterly equal installments, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.